Coeptis Therapeutics Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended | ||
|---|---|---|
| June 30, 2025 | June 30, 2024 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(7,755,527) | $(6,036,733) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 590,606 | 500,422 |
| Forgiveness of interest | 19,447 | – |
| Right of use asset amortization | 20,218 | – |
| Amortization of debt discount | 487,641 | 150,000 |
| Change in fair value of derivative liability warrants | – | 114,375 |
| Stock based compensation | 788,752 | 708,459 |
| Shares issued for non-employee services | 2,407,570 | 1,100,100 |
| Warrants issued for services | 824,295 | 8,150 |
| Change in fair value of derivative liability | (1,041,484) | – |
| Change in fair value of derivative liability warrants | 108,000 | – |
| Loss on shares issued for conversion of debt | – | 77,250 |
| Debt converted to equity | 168,113 | – |
| Unrealized gain on marketable securities | (390,566) | – |
| (Increase) decrease in: | ||
| Accounts receivable | (30,000) | – |
| Interest receivable | – | (152,104) |
| Prepaid assets | (159,237) | 91,825 |
| Right of use asset/liability | (20,568) | (20) |
| Increase (decrease) in: | ||
| Accounts payable | (240,939) | (138,547) |
| Accrued expenses | (320,675) | 256,702 |
| Customer deposit | (218,555) | – |
| NET CASH USED IN OPERATING ACTIVITIES | (4,762,909) | (3,320,121) |
| INVESTING ACTIVITIES | ||
| Increase in subscription receivable in exchange for cash | – | (100,000) |
| NET CASH USED IN INVESTING ACTIVITIES | – | (100,000) |
| FINANCING ACTIVITIES | ||
| Proceeds from notes payable | 990,000 | 1,850,000 |
| Repayment of notes payable | (218,750) | (587,500) |
| Warrants issued for cash | 500 | 500,000 |
| Cash received for stock subscription | – | 50,000 |
| Preferred stock offering | 5,455,000 | 1,693,562 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 6,226,750 | 3,506,062 |
| NET INCREASE (DECREASE) IN CASH | 1,463,841 | 85,941 |
| CASH AT BEGINNING OF PERIOD | 532,885 | 1,469,134 |
| CASH AT END OF PERIOD | $1,996,726 | $1,555,075 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES | ||
| Interest paid | $4,386 | $4,386 |
| Taxes paid | $– | $– |
| SUPPLEMENTAL NON-CASH DISCLOSURES | ||
| Shares issued for the conversion of debt | $894,056 | $868,750 |
| Subscriptions receivable | $– | $4,100,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.